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Morbillivirus  neutralising  antibodies  are  traditionally  measured  using  either  plaque  reduction  neutrali-
sation  tests  (PRNTs)  or live  virus  microneutralisation  tests  (micro-NTs).  While  both  test formats  provide
a reliable  assessment  of the  strength  and  specificity  of the  humoral  response,  they  are  restricted  by the
limited  number  of viral  strains  that can be studied  and  often  present  significant  biological  safety  concerns
to the operator.  In this  study,  we  describe  the  adaptation  of  a replication-defective  vesicular  stomatitis
virus  (VSVG)  based  pseudotyping  system  for  the  measurement  of  morbillivirus  neutralising  antibodies.
By  expressing  the  haemagglutinin  (H)  and  fusion  (F)  proteins  of  canine  distemper  virus  (CDV)  on  VSVG
pseudotypes  bearing  a luciferase  marker  gene,  neutralising  antibody  titres  could  be  measured  rapidly  and
with high  sensitivity.  Further,  by  exchanging  the  glycoprotein  expression  construct,  responses  against
distinct  viral  strains  or  species  may  be  measured.  Using  this  technique,  we  demonstrate  cross  neutral-PRV
seudotype
isation  between  CDV and  peste  des  petits  ruminants  virus (PPRV).  As  an  example  of  the  value  of  the
technique,  we  demonstrate  that UK  dogs  vary  in  the  breadth  of  immunity  induced  by  CDV vaccina-
tion;  in some  dogs  the  neutralising  response  is  CDV-specific  while,  in  others,  the  neutralising  response
extends  to  the  ruminant  morbillivirus  PPRV.  This  technique  will  facilitate  a comprehensive  comparison
of  cross-neutralisation  to  be conducted  across  the  morbilliviruses.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license∗ Corresponding author at: MRC-University of Glasgow Centre for Virus Research,
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1. Introduction
Paramyxoviruses are widespread in nature [1–5] and species
such as bats and rodents harbour many more as yet uncharac-
terised morbilliviruses with potential for zoonotic spread [6]. While
molecular analyses may  detect the presence of viral nucleic acid
within an organism, studying the serological response of a host
species to such pathogens is critical for determining both the level
of morbillivirus exposure in a population and the extent of the
immune response elicited by both natural exposure and vacci-
nation. However, serological studies are often hampered by the
inability to isolate replication competent primary strains of virus.
Further, the propagation of primary strains of some morbilliviruses
may  present a significant biological hazard to either humans or
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ivestock animals, requiring access to high level bio-containment
acilities to prevent the inadvertent release of the pathogen into the
ommunity. Many of the existing experimental systems for mea-
uring neutralising antibodies to morbilliviruses utilise cell culture
dapted strains of virus. During the adaptation process, the bio-
ogical properties of the virus may  alter dramatically to suit the
ew ex vivo environment. For example, the cell-culture adapted
trains of measles virus (MeV) such as Edmonston and Hallé attach
o target cells by binding to the complement regulatory protein
D46 [7,8]. In contrast, primary strains of virus require an inter-
ction with signaling lymphocytic activation molecule (SLAM-F1,
D150) [9–12], a molecule found subsequently to be the primary
eceptor for all morbilliviruses on lymphoid cells (reviewed in [13]),
r nectin-4 (PVRL-4), the cellular receptor for morbilliviruses on
pithelial cells [14–17]. As the receptor binding domain of the
orbilliviral haemagglutinin is a target for neutralising antibod-
es [18], alterations in the receptor binding domain that confer
LAM-independent infection upon cell culture-adapted strains of
irus (e.g. vaccine strains) may  alter the antigenicity of the viral
aemagglutinin and thus modulate the sensitivity of the virus to
eutralising antibodies. Indeed, while phylogenetically all mor-
illiviruses are closely related, with each viral species forming a
ingle serotype [19,20], genotype-specific neutralising antibodies
gainst MeV  have been revealed by pre-absorbing sera from natu-
ally infected individuals with cells expressing the haemagglutinin
f a vaccine strain of virus [21].
In order to circumvent the use of cell culture-adapted mor-
illiviruses in live virus neutralisation assays, systems have been
eveloped to facilitate the isolation and culture of primary strains
f virus. By engineering Vero cells to stably express the SLAM
olecule from the natural host species of the virus [22,23], the cells
rovide a substrate with which neutralising antibodies against pri-
ary strains of virus may  be quantified in live virus-based assays
24]. Unfortunately, the isolation of primary strains of morbil-
iviruses generally requires access to fresh tissue samples collected
ost mortem, and even then not all primary isolates of virus grow
n SLAM-expressing cells [22]. An alternative approach to the
easurement of neutralising antibodies is to generate viral pseudo-
ypes bearing both the haemagglutinin (H) and fusion (F) proteins
f the virus [9,22]. While the H protein is the primary target for
eV  neutralising antibodies, antibodies recognising the F pro-
ein also contribute to a lesser extent to neutralisation [25]. Thus
iral pseudotypes bearing both H and F should recapitulate the
eutralising response in toto. MeV  H and F have been expressed
uccessfully on retroviral pseudotypes [26], while canine distem-
er virus (CDV) H and F pseudotypes have been generated by using
 replication-defective vesicular stomatitis virus (VSV) [27]. These
VSVG” pseudotypes express the CDV H and F on their surface
22], and thus retain the receptor binding specificity of the primary
solate. Accordingly, they should recreate the sensitivity to neutral-
sing antibody of the parent CDV strain. As the viral particles are
erived from VSV, neutralisation assays should not be constrained
y the ability of the primary morbillivirus to grow in the target cells.
n addition, as the morbilliviral H and F glycoproteins expressed
n the VSV pseudotypes are provided in trans from transfected
lasmids, the amino acid sequences of the H and F are not sub-
ect to the antigenic drift that affects stocks of live virus following
epeated in vitro passage. In effect, viral pseudotypes “freeze the
irus in time”, ensuring that the neutralising response is always
easured against virions with identical haemagglutinins, facili-
ating comparisons between animals, viruses and sampling dates.
oreover, neutralising determinants may  be mapped on the viral
lycoproteins by site-directed mutagenesis.
Globally, CDV is the second most common cause of death due to
nfectious disease in domestic dogs. However, CDV is not solely
 pathogen of dogs, it is a widespread pathogen of carnivores4 (2016) 814–822 815
[28], infecting also ferrets, martens, lions, hyenas, tigers, seals and
primates [1–5,29–33]. The catastrophic effects of CDV infection
on endangered lion, tiger and giant panda populations [30,34,35]
have heightened awareness of CDV as an ever-present threat to
increasingly fragile ecosystems. In contrast, the prevalence of PPRV
appears to be increasing globally, with recent outbreaks in Tibet
and China (2007) and across North Africa from Morocco to Tunisia
(2008–2011) [36,37]. PPRV causes a devastating disease in small
ruminants, threatening both food security and the livelihoods of
smallholders. Whether the increase in PPRV is linked to the global
eradication of rinderpest, an example of a virus invading a vacated
niche [38], remains to be established, however the threat posed
by PPRV to the global livestock industry is now significant. Recent
outbreaks in Turkey have increased concern that PPRV may  spread
westward across Europe [39]. If the global threat from viruses such
as CDV and PPRV is to be contained, improved rapid, sensitive and
specific diagnostic assays are required. Such assays will inform
future vaccination programmes, identify potential host populations
that might be targeted for surveillance and provide an early war-
ning of impending outbreaks of infection.
The measurement of neutralising antibodies to CDV is routinely
performed using live virus microneutralisation tests, a test for-
mat  that is slow and relies on the visual recording of a cytopathic
effect. In contrast, the majority of PPRV antibody tests use enzyme-
linked immunosorbent assays (ELISAs), primarily because PPRV
microneutralisation tests are labour-intensive and require access
to high-level biocontainment facilities. Both CDV  and PPRV neutral-
isation assays are limited to a small number of cell culture-adapted
strains of virus. As such, there is currently no means to assess accu-
rately whether there are qualitative differences in the specificity
of the neutralising antibodies present in either convalescent sera
or sera from vaccinates. Our aim was to develop a flexible sys-
tem with which we could measure neutralising responses against
diverse strains of virus rapidly and with a high sensitivity. Here,
we describe the production of VSVG pseudotypes bearing CDV  H
and F glycoproteins and their use in assays for neutralising antibod-
ies. By coupling VSVG(CDV) with SLAM expressing target cells,
we demonstrate that morbillivirus pseudotypes may  be used for
the sensitive, rapid and reliable measurement of virus neutralising
antibodies.
2. Materials and methods
2.1. Cell lines and viruses
HEK293 [40] and HEK293T cells (henceforth referred to as
293 and 293T) were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% foetal bovine serum,
100IU/ml penicillin, 100 g/ml streptomycin, 2 mM  glutamine and
0.11 mg/ml  sodium pyruvate (complete medium). Medium for
293T cells was  supplemented with 400 g/ml G418 (Geneticin®,
Life Technologies Ltd.). Vero (African green monkey) cells [41] were
maintained in complete medium while Vero-dogSLAM cells were
maintained in complete medium supplemented with 400 g/ml
G418. All media and supplements were obtained from Life Tech-
nologies Ltd., Paisley, UK. The Onderstepoort strain of CDV was
obtained from a proprietary DHPPi vaccine (Nobivac, Merck Ani-
mal  Health), the A94-11-14, A91-11-15 [42] and A92-27-4 [43]
strains were obtained from Ed Dubovi, Cornell University. A94-11-
14 and A91-11-15 were propagated in mitogen-stimulated canine
peripheral blood mononuclear cells while the Onderstepoort and
A92-27-14 strains were maintained in Vero cells. The Snyder Hill
strain of CDV [44] and Vero-dogSLAM cells [45] were obtained from
Louise Cosby, Queens University Belfast; the Snyder Hill strain was
propagated in Vero-dogSLAM cells.
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.2. Serum samples
Sera submitted previously to the Veterinary Diagnostic Ser-
ices laboratory at the University of Glasgow for post-vaccination
DV antibody titre testing were derived from domestic dogs in
he United Kingdom. Additional samples were obtained from dogs
nd lions in Tanzania and diverse mesocarnivore species in Rus-
ia. Ruminant sera were collected from ruminants in Tanzania, and
xperimentally infected ruminants.
.3. Eukaryotic expression vectors and recombinant viruses
The recombinant vesicular stomatitis virus (VSV) in which the
lycoprotein (G) gene has been deleted (VSVG) and replaced
ith firefly luciferase (luc) has been described [27,46] and was
indly provided by Michael Whitt, Memphis, TN, USA. An ini-
ial stock of VSVGluc bearing VSVG was used to infect 293T
ells transfected with the VSV-G expression vector pMDG [47].
SVGluc (VSVG) pseudotypes were recovered, titrated on 293T
ells and used to prepare a working stock of VSVGluc (VSV-G)
seudotypes. To prepare CDV H and F expression constructs, viral
NA was prepared from CDV pelleted by centrifugation (QIAamp
iral RNA Mini kit, Qiagen), used to prepare first strand cDNA
Transcriptor First Strand cDNA Synthesis Kit, Roche), and then
sed as template in PCR reactions with the following primers:
DV H Sal: 5′-GTCGAC-ACC-ATGCTCCCCTACCAAGACAAGGT-3′,
DV H Not: 5′-GGGCGGCCGC-TTAACGGTTACATGAGAATCTTA-3′:
DV F Sal: 5′-GGGTCGAC-ACC-ATGCACAGGGGAATCCCCAAAAG-
′ and CDV F D633 Not: 5′-GGGCGGCCGC-TTGCTAGCGTCTT-
TACAACAGTAAATCAGCA-3′ (Expand High Fidelity PCR sys-
em, Roche). Peste des petits ruminants (PPRV) H and F
DNAs were amplified from the Nigeria 75/1 encoding plas-
id  pCI-PPRV-delL [48] using the primers PPRV-H-NotWtF:
′-CCGGCGGCCGCACCATGTCCGCACAAAG-3′, PPRV-H-BamH1R:
′-GGGGGATCCTCAGACTGGATTACATGTT-3′, PPRV-F-Wt-NotF:
′-GGGGCGGCCGCACCATGCATGCGCCGA-3′, PPRV-F-BamH1-WtR:
′-GGGGGATCCGCCTACAGTGATCTCACGT-3′, PPRV-F-BamH1-
633R: 5′-GGGGGATCCTGGTTATCTCCCCTTACAG-3′. Amplifica-
ions were performed with the following thermocycling condi-
ions: denaturation at 94 ◦C for 5 min, followed by 35 cycles of 94 ◦C
or 30 s, annealing at 50 ◦C for 60 s and extension at 72 ◦C for 120 s,
ith a final extension at 72 ◦C for 10 min. Products were digested
ith the enzymes SalI  and NotI and cloned into the eukaryotic
xpression vector VR1012 (Vical Inc.). Canine SLAM-F1 (dogSLAM)
as amplified from total RNA prepared from mitogen-stimulated
anine peripheral blood mononuclear cells using PCR (Q5® High-
idelity DNA Polymerase, New England Biolabs) and the primers
ogSLAM Bgl: 5′-GCTCAGATCTGAGAGCTTGATGAATTGCCCAG-3′
nd dogSLAM Sal: 5′-GCTCGTCGACGCTCTCTGGGAACGTCAC-3′.
mplifications were performed with the following thermocycling
onditions: denaturation at 98 ◦C for 30 s, followed by 30 cycles
f 98 ◦C for 10 s, annealing at 65 ◦C for 30 s and extension at 72 ◦C
or 60 s, with a final extension at 72 ◦C for 2 min. The amplified
DNA was cloned into the pDisplay eukaryotic expression vector
Life Technologies, Paisley, UK) using BglII and SalI. The nucleic
cid sequences of all amplified cDNAs were determined exter-
ally by Sanger dideoxy chain termination sequencing (LIGHTrun
equencing Service, GATC Biotech AG, Cologne, Germany). All
ligonucleotide primers were obtained from Integrated DNA
echnologies, Leuven, Belgium.
To prepare VSVGluc (CDV) and VSVGluc (PPRV) pseudo-
ypes, 293T cells were transfected with the H and F expression vec-
ors from CDV and PPRV respectively, followed by super-infection
ith VSVGluc (VSVG) as described [27,46]. Supernatants were
arvested 48 h post-infection, aliquoted and frozen at -80 ◦C. The
itre of each viral pseudotype stock was estimated by preparing4 (2016) 814–822
serial dilutions in triplicate and plating onto 293dogSLAM cells fol-
lowed by incubation for 48–72 h at 37 ◦C, at which time luciferase
substrate was  added (Steadylite plusTM, Perkin Elmer) and the sig-
nal analysed on a Microbeta 1450 Jet luminometer (Perkin Elmer).
The viral titre (50% tissue culture infectious dose (TCID) was calcu-
lated using the Spearman–Kärber formula [49].
2.4. Canine SLAM expressing 293 cells
To prepare target cells for the VSV-G(CDV) pseudotypes,
293 cells were transfected with pDisplay-dogSLAM using linear
polyethylenimine, MW 25,000 (Polysciences Inc., Park Scientific,
Northampton, UK) and selected in complete medium supple-
mented with 800 g/ml G418. The stably transfected 293-dogSLAM
cells were expanded and the surface expression of SLAM confirmed
by flow cytometry using rabbit polyclonal anti-HA tag (Sigma,
Poole, UK) followed by phycoerythrin (PE)-conjugated goat anti-
rabbit IgG (Sigma) on a BD Accuri flow cytometer (BD, Oxford,
UK). SLAM-F1-expressing cells were compared with cells stably-
transfected with the empty vector. The analysis gate was set such
that <1% of vector-only control cells were deemed positive.
2.5. Live virus microneutralisation assay
Neutralising antibodies were determined by live virus neutral-
isation assay [50] on Vero cells using the Bussell variant of the
Onderstepoort strain of CDV [51]. Four-fold dilutions of each serum
sample (ranging from a dilution of 1:16 to 1:16384) were prepared
in quadruplicate in complete medium in a 96-well flat bottom plate.
∼100 TCID50 of virus was added to each serum dilution and incu-
bated in the dark at room temperature for 1 h, followed by a further
hour at 4 ◦C. 1 × 104 Vero cells were then added to each well and the
plates were incubated at 37 ◦C for three days prior to microscopic
examination for cytopathicity.
2.6. Pseudotype-based neutralisation assay
2 × 104 293-dogSLAM cells were plated into each well of a
96-well white flat-bottomed plate (Culturplate-96, Perkin Elmer,
Coventry, UK). Four-fold serum dilutions were prepared in tripli-
cate in complete medium ranging from 1:8 to 1:32768. The diluted
serum samples were then added to the 293-dogSLAM cells followed
by 2.5 × 103 TCID50 of VSVG(CDV) pseudotype. Plates were incu-
bated for 48–72 h at 37 ◦C, at which time luciferase substrate was
added (Steadylite plusTM, Perkin Elmer) and the signal analysed on
a Microbeta 1450 Jet luminometer (Perkin Elmer). Antibody titres
were calculated by interpolating the point at which there was a
90% reduction in luciferase activity (90% neutralisation, inhibitory
concentration 90 or IC90) [52].
3. Results
VSVG(CDV) pseudotypes bearing a green fluorescent protein
(GFP) reporter gene were used previously to define determinants
of viral cell tropism [22]. In order to facilitate high throughput
screening of sera for neutralising antibodies, VSVG(CDV) pseu-
dotypes were prepared carrying a firefly luciferase marker gene
(luc). As expression of the luciferase reporter gene was very low in
Vero-dogSLAM cells, target cells were generated based on 293 cells.
Stable transfection and expression of canine SLAM was confirmed
by flow cytometry (65.4% SLAM positive, Fig. 1A). Next, the suscep-
tibility of the 293-dogSLAM cells to infection with VSVG(CDV)
pseudotypes bearing H and F proteins from the Onderstepoort, A94-
11-14, A94-11-15 and A92-27-4 strains was  investigated (Fig. 1B).
Of the four strains tested, the two Vero cell-adapted isolates
(Onderstepoort and A92-27-4) gave higher activities consistently,
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Fig. 1. Infection of 293-dogSLAM cells with VSVG(CDV) pseudotypes. (A) 293 cells were stably transfected with a canine SLAM expression vector to generate “293-dogSLAM”
cells.  Expression of the HA-tagged SLAM was  confirmed by flow cytometry using rabbit anti-HA tag (blue line) in comparison with vector only control cells (black line). (B)
VSVG(CDV)  pseudotypes bearing the Onderstepoort (ONDS), A94/11/14, A94/11/15 and A92/27/14 H and F proteins, or bearing no H and F proteins (control), were prepared
in  parallel and plated onto 293-dogSLAM. Luciferase activity was  measured 72 h post infection. (C) Titration of VSVG(CDV) (Onderstepoort) on 293-dogSLAM. Serial two-fold
dilutions of the pseudotypes were prepared in quadruplicate and plated on to 293-dogSLAM. Luciferase activity (CPM) was read at 72 h post-infection, the TCID50 was then
calculated using the Spearman–Kärber method. The last luciferase positive dilution representing the end-point of the titration is arrowed. (D) Neutralisation of VSVG(CDV)
pseudotypes by a CDV-positive serum. CDV-positive and negative sera were incubated with three input amounts of viral pseudotypes, equivalent to 2.5 × 102, 2.5 × 103
and 2.5 × 104 TCID50/well in triplicate and plated onto 293-dogSLAM cells, luciferase activity (CPM) was read at 72 h post-infection. * denotes no serum control, arbitrarily
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eferred to the web  version of this article.)
hile the two PBMC-grown viruses gave lower mean activities.
LAM-dependent infection of the 293-dogSLAM cells was  con-
rmed by comparison with 293 cells transfected with pDisplay only
Supplementary Fig. 1). Titration of VSVG(CDV) Onderstepoort
seudotypes by serial dilution on 293-dogSLAM cells indicated that
1 × 109 CPM of luciferase activity equated to ∼1.1 × 107 TCID50
Fig. 1C).
Next, the application of the VSVG(CDV) pseudotypes to assays
or virus neutralising antibodies was investigated. Three input
mounts of VSVG(CDV) Onderstepoort strain pseudotypes were
ompared (Fig. 1D), equivalent to 2.5 × 102, 2.5 × 103 and 2.5 × 104
CID50 per well, our objective being to minimise the volume of
iral pseudotypes required per assay while ensuring the accuracy
f the determination of antibody titre. Irrespective of the amount
f input virus, the measured antibody titre (90% neutralisation)
emained consistent, mean titres of 966, 922 and 970 for inputs
f 2.5 × 102, 2.5 × 103 and 2.5 × 104 TCID50 per well respectively.
owever, given the variability observed at the lowest input of virus
2.5 × 102 TCID50), we elected to use an input of 2.5 × 103 TCID50 per
ell, equivalent to approximately 1 × 107 CPM of luciferase activity.
CDV neutralising antibody titres in 190 serum samples submit-
ed to the University of Glasgow Companion Animal Diagnostic
aboratory for diagnostic testing were compared between a clas-
ical “live virus” microneutralisation assay [50] on Vero cells
endpoint titre calculated using Spearman–Kärber method) and
SVG(CDV) pseudotypes on Vero-dogSLAM cells (90% reduction
n luciferase activity) [52]. The two assays correlated well (Fig. 2),. (For interpretation of the references to colour in this figure legend, the reader is
revealing a Spearman r coefficient of 0.76 (95% confidence interval
0.69–0.81, p < 0.0001), suggesting that the pseudotype assay was a
reliable substitute for the live virus-based assay. In general, titres
obtained with the pseudotype-based assay were ∼10-fold higher
than those obtained with the live virus based assay. Of the 44 sam-
ples that scored negative by live virus assay (titre <8), 9 (20%) were
found to have detectable neutralising antibody activity by pseudo-
type assay (red circles, Fig. 2). Given that the neutralising activity
in the 9 samples was  confirmed to be CDV-specific (no neutral-
ising activity was  detected against VSVG(VSV-G) pseudotypes),
these data suggest that the enhanced sensitivity of the pseudo-
type assay and capacity for inclusion of unrelated virus controls
may  facilitate the discrimination of false negatives. At present, live
virus microneutralisation tests for CDV antibody lack the capacity
for confirmation of the specificity of the test.
34 sera that scored weakly positive by the live virus based assay
(titres in the range 11–88, median value 16) were found to have
titres of <16 by the pseudotype assay. Given the enhanced sensi-
tivity of the pseudotype-based assay, we would predict that any
sample yielding a low titre with the live virus microneutralisa-
tion test would give a higher titre with the pseudotype-based test.
Accordingly, the finding that the 34 sera reported as weakly pos-
itive in the live virus microneutralisation test were negative by
the pseudotype test may  indicate that these samples represented
false positives by the live virus microneutralisation assay. If the 34
sera that scored weakly positive by live virus assay are excluded
from the comparison between the tests the correlation between
818 N. Logan et al. / Vaccine 3
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Fig. 2. Comparison of neutralising antibody titres calculated using replication com-
petent CDV virus (Bussell strain of Onderstepoort) and VSVG (CDV) pseudotypes
expressing the Onderstepoort H and F glycoproteins from the Nobivac DHPPi vac-
cine. 9 of the 44 samples that scored negative by live virus assay (titre <8) were
found to have detectable neutralising antibody activity by pseudotype assay (red
circles) suggesting that the pseudotype assay facilitated the detection of a num-
ber of false negative samples. Spearman r coefficient 0.76 (95% confidence interval
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gure legend, the reader is referred to the web  version of this article.)
he two assays rises to r = 0.91 (95% confidence interval 0.87–0.93,
 < 0.0001, n = 168).
False positives at high serum concentrations are not uncommon
ith live virus microneutralisation tests and the definition of a reli-
ble cut-off point in the absence of a “gold-standard” diagnostic test
s problematic. A significant concern with live virus-based assays is
heir reliance on visual inspection of a cytopathic effect within the
onolayer of cells for endpoint determination. Non-specific toxic
ffects of the serum sample, especially at high serum concentra-
ions, may  alter the morphology of the monolayer, interfering with
he interpretation of the assay end-point. The enhanced sensitiv-
ty of the pseudotype based assay reduces the susceptibility of the
ssay to non-specific toxic effects and accordingly may  facilitate
he detection of virus neutralising antibodies at lower dilutions of
erum, circumventing the potential toxic effects of such sera.
An alternative consideration is that the sera scoring weakly pos-
tive by live virus neutralisation test might be reacting with an
ntigen present on live virus that is absent from VSVG(CDV)
seudotypes. As the Bussell strain of CDV used in this study
as propagated in Vero (African green monkey kidney epithe-
ial) cells while the VSVG(CDV) pseudotypes were generated in
93T (human embryonic kidney) cells, it is conceivable that the
eak reactivity detected in the live virus assay reflects an activity
gainst a Vero cell-derived antigen that is absent from the 293T-
erived VSVG(CDV) pseudotypes. Similarly, as the live virus assay
s SLAM-independent, it is also possible that the live virus assay
etects a very weak response against distinct epitopes on the viral
lycoproteins that are critical for SLAM-independent infection but
re rendered insignificant in the presence of a high affinity SLAM-
nteraction as in the VSVG(CDV) pseudotype assay.
It is widely assumed that antibody responses to CDV form a sin-
le serotype, however the majority of assays performed to date
ave utilised a limited number of Vero cell-adapted strains of virus.
f we are to assess accurately the neutralising response against
eld strains of virus, the assays should be performed using bio-
ogically relevant, non-cell culture adapted strains of virus. To
nvestigate the feasibility of this approach we compared the neu-
ralisation sensitivity of VSVG(CDV) pseudotypes bearing the H
nd F proteins of the primary A94-11-15 strain with those bearing4 (2016) 814–822
the cell culture adapted Onderstepoort strain. A94-11-15 is an iso-
late from an African dog collected during the 1994 CDV outbreak in
the Serengeti [42]. The Onderstepoort and A94-11-15 pseudotypes
were screened against a batch of dog sera collected in the Serengeti
region between 2007 and 2011. Firstly, a strong positive correlation
was observed between the antibody titres estimated using the clas-
sical live virus microneutralisation test (ONDS micro-NT) and the
pseudotype-based (VSVG(ONDS)) test (r = 0.79, p < 0.0001; Fig. 3).
When the analysis was repeated using VSVG(A94-11-15) pseudo-
types, a significant, but weaker correlation was  noted between the
titres estimated using the ONDS micro-NT and the VSVG(A94-11-
15) pseudotypes (r = 0.65, p < 0.0001; Fig. 3). The ONDS micro-NT
measures a reduction in the cytopathic effect observed in Vero
cells following infection. In contrast, the VSVG pseudotype test
measures inhibition of viral entry mediated by canine SLAM. Given
that the A94-11-15 strain is a SLAM-dependent field strain while
Onderstepoort is a cell culture-adapted, SLAM-independent strain,
it is likely that differences would be evident between the two assay
systems. When the titres obtained with VSVG pseudotypes bear-
ing the ONDS and A9-11-15 glycoproteins were compared, a highly
significant correlation was observed (r = 0.90, p < 0.0001; Fig. 3),
perhaps suggesting qualitative and quantitative differences in the
neutralising antibodies that are being measured on Vero cells and
293dogSLAM cells.
In order to define further the viral species-specificity of the
pseudotype based test, we compared the neutralisation sensitivity
of VSVG (CDV) pseudotypes, with pseudotypes prepared using
the H and F proteins of the genetically distant morbillivirus, PPRV
(peste des petits ruminants). As the degree of antigenic-relatedness
varies between morbilliviruses, we  would predict that a high
titre antibody response against CDV would encompass weaker,
cross-neutralising activity against PPRV. Conversely, a high titre
anti-PPRV serum would neutralise CDV pseudotypes more weakly.
The sensitivities of VSVG (CDV) pseudotypes and VSVG (PPRV)
pseudotypes to neutralisation by sera from animals exposed to, or
immunised against, CDV and PPRV was compared. The CDV sera
consisted of dog sera from the UK, Tanzania and Russia, and PPRV
sera consisted of ruminants from Africa and Asia. The PPRV sera dis-
played titres of neutralising antibodies that were ∼100-fold higher
against VSVG (PPRV) than against VSVG (CDV) (Fig. 4). Con-
versely, the CDV sera neutralised VSVG (CDV) ∼100-fold more
efficiently than VSVG (PPRV) (Fig. 4). Using a general linear model
(GLM), the log10-transformed neutralising titres of the dog sera
against CDV and the ruminant sera against PPRV, were compared
with the log10-transformed neutralising titres of the dog sera
against PPRV and the ruminant sera against CDV. The results of
the GLM showed the difference to be highly significant (p < 0.0001).
Thus, the specificity of the CDV neutralising response could be con-
firmed by comparing the responses against CDV with those against
PPRV; a higher titre against CDV than PPRV would suggest that the
animal was  exposed primarily to CDV.
Neutralising responses against CDV and PPRV were compared in
a collection of post-CDV vaccination sera from dogs (Fig. 5). Given
that the sera were derived from dogs in the UK, the animals could
not have been exposed to PPRV and any neutralising activity against
PPRV would represent a cross-neutralising anti-CDV response.
While some sera appeared to be CDV-specific (Fig. 5A–D), other sera
displayed strong cross reactivity with PPRV (Fig. 5E–H). These data
would suggest the existence of epitopes that are either relatively
conserved across species of morbillivirus (as in Fig. 5E–H) or which
are specific to a single viral species such as CDV (Fig. 5A–D). As illus-
trated in Fig. 4, the degree of cross neutralisation varies from animal
to animal and may  reflect a combination of both the host’s ability to
mount a humoral response to the virus and the nature of the expo-
sure to the viral antigen. In order to confirm the specificity of the
neutralising response further, sera were also tested against VSVG
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Fig. 3. Neutralisation of VSVG(CDV) pseudotypes bearing Onderstepoort (ONDS) and A94-11-15 glycoproteins by sera from African dogs only; comparison with classical
“live  virus” micro-neutralisation test (micro-NT). Each serum was  tested in triplicate (VSVG(CDV) pseudotype assay) or quadruplicate (micro-NT). Antibody titres against
VSVG(CDV)  pseudotypes were calculated based on 90% reduction of infectivity while 
coefficients were calculated for each plot.
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Fig. 4. Cross-neutralisation of VSVG (CDV) and (PPRV) pseudotypes by sera raised
against PPRV and CDV. Sera from ruminants () exposed or vaccinated against PPRV,
or  dogs (O) vaccinated against or naturally exposed to CDV were screened for neu-
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and whether this impacts upon receptor usage and sensitivity toralising antibodies against CDV or PPRV. Each point represents the serum titre that
educed luciferase activity by 90% relative to the no serum control as calculated by
erial dilution.
VSV) pseudotypes. Sera that showed neutralising activity against
oth CDV and PPRV did not neutralise the VSVG (VSV) pseu-
otypes, confirming the specificity of the response. Weak activity
gainst VSVG (VSV) observed at high serum concentrations in
ome samples (e.g. Fig. 5B and E) could be confirmed as non-specific
nhibitory activity as VSV is not present in the UK. In selecting a
tringent 90% reduction in infectivity as the basis for calculation of
he antibody titre, such weak, non-specific neutralising activity is
liminated and samples with such activity are scored as negative.
. Discussion
In this study, we describe the measurement of morbilliviral neu-
ralising antibodies using a viral pseudotype-based assay. The aim
f the study was to develop an assay that was rapid, sensitive and
hich enabled the analysis of neutralising responses against field
trains of virus without a requirement for virus adaptation to Vero
ell culture. One of the primary concerns with adapting viruses
o cell culture is that the cell-culture adapted viruses no longer
eflect the neutralisation sensitivity of field strains of the virus. Field
trains of virus are generally isolated onto cells expressing the cog-
ate SLAM molecule, while cell culture-adapted strains of virus are
ble to replicate in SLAM-negative cell lines such as Vero. The naturemicro-NT titres were calculated using the Spearman–Kärber formula. Spearman r
of the viral receptor utilised by a virus can determine the sensitiv-
ity of the virus to neutralising antibodies. Consequently, alterations
in receptor usage during adaptation for in vitro growth may  alter
the neutralisation sensitivity of the virus. In regard to the genus
Morbillivirus, this phenomenon has been observed with measles
virus, where neutralising epitopes were mapped to the receptor
binding sites on the haemagglutinin of the virus [53] (Fig. 6). For
example, the activity of the neutralising monoclonal antibody 2F4,
an antibody that targets a conserved neutralising epitope, is dis-
rupted by mutations in residues D505 and R533 of the measles
haemagglutinin (Fig. 6) [18]. Mutations in residues D505 or R533
also disrupt the haemagglutinin-SLAM-F1 interaction, suggesting
that escape from neutralisation by antibodies such as 2F4 may drive
the emergence of SLAM (and nectin-4) independent strains [18].
Accordingly, in vitro systems for measuring neutralising antibodies
should utilise SLAM-F1, or nectin-4-expressing cell lines if they are
to recapitulate fully the expected neutralisation sensitivity of the
virus in vivo. In this study, we  generated canine SLAM-expressing
293 cells as an indicator cell line for the neutralisation assay.
The “293dogSLAM” cells expressed the VSVG-encoded luciferase
gene efficiently. Using these target cells, we  generated a luciferase-
based assay that was approximately 10-fold more sensitive than
the conventional live virus based microneutralisation assay and
which yielded data in three days with no requirement for oper-
ator interpretation of cytopathic effect by visual inspection. As
a glow luciferase-based system, the assay is amenable to high-
throughput screening using small sample volumes. Uniquely, the
modular nature of the VSVG pseudotyping system facilitates the
preparation of pseudotypes bearing a range of heterologous glyco-
proteins from diverse, primary strains of CDV. In proof-of-concept,
we prepared pseudotypes bearing H and F glycoproteins from both
the Vero cell-adapted Onderstepoort and A92-27-14 strains, and
the primary field strains A94-11-14 and A94-11-15. Of the CDV
strains tested, the two  Vero cell-adapted isolates (Onderstepoort
and A92-27-4) yielded higher titres during pseudotype production
than the other strains tested, perhaps indicating that adaptation to
in vitro growth altered the biological properties of these viruses,
favouring more efficient pseudotype production. Efficient pseu-
dotyping of morbilliviral glycoproteins on VSV particles requires
optimal H and F expression on the plasma membrane of the trans-
fected 293T cells at the site of VSV assembly and budding. Future
studies should investigate whether field strains of other morbil-
liviruses vary in their relative efficiencies of H and F incorporationneutralising antibodies.
Classical live virus microneutralisation assays or PRNT assays
rely on the visual inspection of the indicator cells for a cytopathic
820 N. Logan et al. / Vaccine 34 (2016) 814–822
10 10 0 100 0 1000 0 10000 0
103
104
105
106
107
108
Serum Dil ution
 
 
CDV
PPRV
VSV
10 10 0 100 0 1000 0 10000 0
103
104
105
106
107
108
Serum Dil ution
L
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
 (
C
P
M
)
CDV
PPRV
VSV
10 10 0 100 0 1000 0 10000 0
103
104
105
106
107
108
Serum Dil ution
 
 
CDV
PPRV
VSV
10 10 0 100 0 1000 0 10000 0
103
104
105
106
107
108
 
 
 
CDV
PPRV
VSV
10 10 0 100 0 1000 0 10000 0
103
104
105
106
107
108
Serum Dil ution
 
 
10 10 0 100 0 1000 0 10000 0
103
104
105
106
107
108
10 10 0 100 0 1000 0 10000 0
103
104
105
106
107
108
10 10 0 100 0 1000 0 10000 0
103
104
105
106
107
108
 
L
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
 (
C
P
M
)
CDV
PPRV
VSV
A B E F
C D G H
Fig. 5. Neutralisation of VSVG (CDV), VSVG (PPRV) and VSVG (VSV) pseudotypes by sera from vaccinated dogs in the UK. While some sera appeared to be CDV-specific
(A–D),  other sera (E–H) displayed broader neutralising activity, neutralising PPRV pseudotypes effectively, albeit with a lower a titre. Absence of neutralising activity against
VSVG  (VSV) pseudotypes confirmed the specificity of the response. Each point represents mean ± SEM.
Fig. 6. Structure of measles virus (MeV H) haemagglutinin (green), highlighting residues involved in SLAM-F1 binding (cyan), nectin-4 binding (magenta) and CD46 binding
(orange). Residues D505 and R533 render measles virus resistant to neutralisation by monoclonal antibody 2F4 and disrupt SLAM-F1 binding [18]. Additional binding sites
for  measles virus neutralising antibodies have been mapped to regions I, II, IV, V and VI [18], site II overlaps the CD46 binding site only, but not the binding sites for SLAM-F1
or  nectin-4.
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ffect or plaque formation. As such, viral entry events that do not
rigger a cytopathic effect or plaque formation will not be quanti-
ed and neutralisation of such infectivity will not be recorded. In
ontrast, the pseudotype based neutralisation assay measures neu-
ralisation of viral entry mediated by the viral receptor SLAM-F1.
ccordingly, all successful entry events that lead to gene expres-
ion are detected by measuring luciferase activity. Thus, while a
ive virus assay measures the net result of a complex series of
vents, from entry, through cell-cell spread and cytopathic effect, a
seudotype-based assay focuses solely on antibodies that prevent
iral entry. Given that morbilliviruses have evolved two  distinct
eceptor interactions (SLAM-F1 and nectin-4), it may  be possible to
istinguish antibodies that prevent cell-free virus infection from
hose that prevent cell-cell spread and dissemination. Cell-free
irus infection would be best modelled using SLAM-F1 expressing
arget cells whereas the spread of virus across epithelial barriers
ould be modelled better using nectin-4 expressing target cells.
he pseudotype-based assay system will facilitate the dissection of
he neutralising response and permit the determination of whether
he nature of the viral receptor expressed on the target cell is critical
o the outcome of the assay.
In order to assess the specificity of the system we  generated
seudotypes bearing the H and F glycoproteins of PPRV (Nigeria
5/1 strain). Sera raised against CDV, either through vaccination or
atural exposure, neutralised CDV ∼100-fold more efficiently than
PRV. In contrast, sera raised against PPRV neutralised PPRV pseu-
otypes ∼100-fold more efficiently than CDV pseudotypes. These
bservations reveal two things about the assay system. Firstly, the
pecificity of the CDV response can be confirmed by comparing
gainst a distantly related viral species. The specificity of a low titre
esponse against CDV can be confirmed by analysing in parallel,
he response against PPRV. Secondly, the assay system provides
 simple means of measuring cross-neutralisation between dis-
inct strains and species of virus. Indeed, while some UK dog sera
ppeared to display good neutralisation of PPRV, a pathogen absent
rom the UK, others were largely CDV-specific. These data suggest
hat the humoral responses of UK dogs to vaccination against CDV
iffer in their epitope specificities; some dogs recognising deter-
inants that are broadly conserved between CDV and PPRV while
ther dogs mount a largely CDV-specific response. Recent studies
ave noted that a proportion of human sera contain weak cross-
eutralising antibodies against CDV [54], suggesting that a potent
nti-measles response may  induce a low level cross-neutralising
esponse to CDV. Our data would suggest that the potency of the
eterologous neutralising response is not solely dependent on the
omologous antibody titre; rather there are qualitative differences
n the breadth of the neutralising response to infection between
osts. Whether such differences reflect the variable nature of the
ost immune response to vaccination, the antigenicity of the vac-
ine used to elicit the response, or post-vaccination exposure to
eld strains of CDV remains to be established. The significance
f these observations to the breadth of immunity conferred by
accination merits further investigation, both from the perspec-
ive of CDV vaccination where a broader response may protect
gainst diverse field strains of the virus, and from the perspec-
ive of protecting against the threat of zoonotic transmission of
orbilliviruses between species.
Several reports have described the cross-species transmission of
orbilliviruses, including CDV, PDV and PPRV [1–5,29–34,55,56].
ith the global eradication of rinderpest, an ecological niche may
ave been created for related morbilliviruses such as PPRV [57].
imilarly, progress towards the eradication of measles may  leave
umans exposed to an emerging threat from amphotropic viruses
uch as CDV [58]. Preventing such zoonotic transmissions presents
 major challenge to both human and veterinary medicine. For
xample, could measles vaccines protect humans from infection
[
[4 (2016) 814–822 821
with CDV? Recent data would suggest that measles vaccination
does provide partial protection to macaques from infection with
CDV [24]. If vaccination against one morbillivirus species induced
cross-protection against related morbilliviral species, the risks of
zoonoses would diminish markedly. Thus, access to assay systems
that facilitate the accurate, sensitive and reproducible quantifica-
tion of cross-neutralising antibodies will play a key role in selecting
vaccine compositions and regimen that are most likely to prevent
novel morbilliviral epizootics.
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